Our Mission

Our Mission

Our Mission


Overcoming Limitations of Current Treatment Paradigms

Targeting oncogenic mutations has provided clinical benefits to many patients. Unfortunately, while these treatments have generally led to initial clinical responses in patients with specific oncogenic mutations, these responses are often followed by patients becoming resistant to treatment and subsequently relapsing and developing metastatic disease.

At HiberCell, we are utilizing our expertise into drivers of cancer progression and our QuAD3 platform to navigate a deeper understanding of and develop therapeutics targeting the adaptive stress response, which we believe to be responsible for this limited therapeutic efficacy.  Our team is focused on understanding the biology and pathways that can limit the potential long-term benefits of standard-of-care therapies. Our group’s research suggests that one of the key biological drivers of limited treatment benefit is activation of the adaptive stress response. This response can reprogram the phenotype of cancer cells, which promotes their survival in harsh microenvironments by enabling the cells to hide from immune attack and ultimately resist treatment.

Our clinical-stage therapies are designed to modulate the adaptive stress response and provide patients with a novel approach for addressing treatment resistance, cancer relapse and metastasis.

A Differentiated Approach to Improving Treatment Efficacy and Durability

We are a clinical-stage oncology company focused on discovering and developing novel therapies that target the pathways of the adaptive stress response and immune modulation in order to provide patients with treatment options that help them live longer, cancer-free lives. HiberCell was launched in 2019 with investor support from ARCH Venture Partners and other leading life science investors.

Our initial research on cancer dormancy was pioneered by Dr. Julio Aguirre-Ghiso and his laboratory at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. Building on the connectivity of the biology between dormancy and the adaptive stress phenotype, HiberCell has built a differentiated pipeline aimed at improving patient outcomes.

Improved Clinical Development and Discovery

Improved Clinical Development and Discovery

Improved Clinical Development and Discovery

We have industry-leading tools for the analysis of patient cohorts. Analysis of this data provides novel phenotypic insights and clinical-genomic observations that we believe will help identify patients who are most likely to respond to our therapies. We believe that combining these data-driven findings with our QuAD³ platform should offer a deeper clinical understanding of the mechanisms of adaptive stress across the oncology landscape as well as other disease areas. Collectively, our goal is to utilize our QuAD³ platform to assist in the development of our current and future therapeutic candidates more efficiently than existing industry tools and aid our therapeutic discovery efforts.

Core Capabilities of our QuAD³ Platform

Discovery engine driving insights from clinical data

Quantum machine learning and ensemble AI approach

Pathway identification, annotation and causal target validation

Biomarker insights to power informed clinical development